MCID: OVR042
MIFTS: 81

Ovarian Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 57 12 76 53 25 75 37 29 55 6 43 3 15
Ovarian Carcinoma 53 25 13 55 73
Ovarian Neoplasm 12 6 73
Adenocarcinoma, Ovarian, Somatic 57 13
Epithelial Ovarian Cancer 75 73
Ovarian Cancer, Somatic 57 13
Neoplasm of Ovary 29 6
Primary Malignant Neoplasm of Ovary 73
Malignant Neoplasm of the Ovary 25
Malignant Tumor of the Ovary 25
Malignant Neoplasm of Ovary 73
Ovarian Carcinoma, Somatic 57
Malignant Tumour of Ovary 12
Malignant Ovarian Tumor 12
Primary Ovarian Cancer 12
Cancer of the Ovary 25
Tumor of the Ovary 12
Ovarian Neoplasms 44
Cancer, Ovarian 40
Ovary Neoplasm 12
Oc 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
ovarian cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 167000
Disease Ontology 12 DOID:2394
ICD10 33 C56
ICD9CM 35 183.0
MeSH 44 D010051
NCIt 50 C4984 C7431
KEGG 37 H00027
SNOMED-CT via HPO 69 263681008 254838004 60718004

Summaries for Ovarian Cancer

NIH Rare Diseases : 53 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and ovarian cancer 1, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is OPCML (Opioid Binding Protein/Cell Adhesion Molecule Like), and among its related pathways/superpathways are MicroRNAs in cancer and fMLP Pathway. The drugs CEA-Scan and Doxil have been mentioned in the context of this disorder. Affiliated tissues include the ovary, ovary and testes, and related phenotypes are abnormality of metabolism/homeostasis and breast carcinoma

OMIM : 57 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000)

UniProtKB/Swiss-Prot : 75 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

MedlinePlus : 43 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

Genetics Home Reference : 25 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

Novus Biologicals : 56 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

Wikipedia : 76 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 36.5 BRCA1 BRCA2 BRIP1 PALB2 PTEN
2 ovarian cancer 1 36.4 AKT1 BRCA1 BRCA2 CDH1 KRAS PIK3CA
3 breast cancer 35.9 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
4 pancreatic cancer 35.3 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 KRAS
5 hereditary site-specific ovarian cancer syndrome 35.3 BRCA1 BRCA2
6 lynch syndrome 34.7 BRAF BRCA1 BRCA2 CTNNB1 KRAS
7 ovary epithelial cancer 34.4 AKT1 BRCA1 BRCA2 CDH1 KRAS PIK3CA
8 ovarian clear cell carcinoma 34.1 KRAS PIK3CA PTEN
9 colorectal cancer 33.5 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
10 endometrial cancer 33.5 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
11 lung cancer 33.4 AKT1 BRAF CDH1 CTNNB1 KRAS MIR146A
12 adenocarcinoma 33.3 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
13 prostate cancer 33.2 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 KRAS
14 testicular germ cell tumor 32.5 AKT1 BRAF MIR200C PTEN
15 endometriosis 32.5 MIR200A MIR200B MIR34C
16 melanoma 32.3 BRAF MIR200A MIR200B MIR200C MIR34C PTEN
17 glioblastoma 32.3 AKT1 BRAF BRCA2 PIK3CA PTEN
18 cowden disease 32.3 AKT1 BRCA1 BRCA2 PIK3CA PTEN
19 fanconi anemia, complementation group a 32.2 BRCA1 BRCA2 BRIP1 PALB2
20 gastrointestinal stromal tumor 31.9 AKT1 BRAF KRAS PTEN
21 breast carcinoma in situ 31.8 BRCA1 BRCA2 CDH1
22 sporadic breast cancer 31.7 BRCA1 BRCA2 PTEN
23 li-fraumeni syndrome 31.7 BRCA1 BRCA2 PTEN
24 familial adenomatous polyposis 31.5 CDH1 CTNNB1 KRAS
25 adamantinoma of long bones 12.3 BRAF BRCA1 BRCA2 CDH1 CTNNB1 KRAS
26 female reproductive organ cancer 12.2 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 KRAS
27 breast-ovarian cancer, familial 1 12.2
28 breast-ovarian cancer, familial 2 12.2
29 breast-ovarian cancer, familial 3 12.2
30 breast-ovarian cancer, familial 4 12.2
31 childhood ovarian cancer 12.2
32 pancreas adenocarcinoma 12.1 AKT1 BRCA2 CDH1 CTNNB1 KRAS PALB2
33 lung cancer susceptibility 3 12.1 AKT1 BRAF CDH1 CTNNB1 KRAS MIR200B
34 brca1 hereditary breast and ovarian cancer syndrome 12.1
35 brca2 hereditary breast and ovarian cancer syndrome 12.1
36 hepatocellular carcinoma 12.1 AKT1 CDH1 CTNNB1 KRAS MIR146A MIR200A
37 gastric adenocarcinoma 12.1 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
38 squamous cell carcinoma 12.1 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
39 squamous cell carcinoma, head and neck 12.1 AKT1 BRAF CDH1 CTNNB1 MIR200A PIK3CA
40 thyroid cancer 12.1 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
41 malignant ovarian surface epithelial-stromal neoplasm 12.1 AKT1 BRCA1 BRCA2 CDH1 KRAS PIK3CA
42 cholangiocarcinoma 12.1 AKT1 CDH1 CTNNB1 KRAS MIR200B PIK3CA
43 respiratory system cancer 12.0 AKT1 CDH1 CTNNB1 KRAS PIK3CA PTEN
44 gastrointestinal system cancer 12.0 AKT1 CDH1 CTNNB1 KRAS PIK3CA PTEN
45 brain cancer 12.0 AKT1 BRAF BRCA2 CTNNB1 PIK3CA PTEN
46 bladder urothelial carcinoma 12.0 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
47 lung squamous cell carcinoma 12.0 AKT1 BRAF CDH1 KRAS PIK3CA PTEN
48 esophageal cancer 12.0 AKT1 CDH1 CTNNB1 KRAS PIK3CA PTEN
49 anaplastic thyroid cancer 12.0 BRAF CDH1 CTNNB1 MIR34C PIK3CA PTEN
50 suppression of tumorigenicity 12 12.0 AKT1 BRAF CTNNB1 PIK3CA PTEN

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
ovarian cancer
dysgerminoma
ovarian papillary adenocarcinoma
serous ovarian cystadenocarcinoma
breast cancer

Lab:
frequent loss of heterozygosity at 6q24-q27


Clinical features from OMIM:

167000

Human phenotypes related to Ovarian Cancer:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 32 HP:0001939
2 breast carcinoma 32 HP:0003002
3 ovarian papillary adenocarcinoma 32 HP:0006774
4 dysgerminoma 32 HP:0100621

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.5 CTNNB1 KRAS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.5 BRAF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.5 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.5 PIK3CA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.5 KRAS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.5 BRAF
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.5 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.5 AKT1 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.5 BRAF PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.5 KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.5 CTNNB1 BRAF AKT1 KRAS PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.5 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.5 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.5 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.5 CTNNB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.5 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.5 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.5 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.5 BRAF
20 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.5 AKT1 PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.5 BRAF CTNNB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.5 CTNNB1 KRAS PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.5 AKT1 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.5 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.5 CTNNB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.5 AKT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.5 CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.5 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.5 CTNNB1 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.5 AKT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.5 KRAS
32 Decreased viability GR00055-A-2 10.35 BRAF KRAS
33 Decreased viability GR00106-A-0 10.35 KRAS
34 Decreased viability GR00221-A-1 10.35 CDH1 KRAS
35 Decreased viability GR00221-A-2 10.35 BRCA1 KRAS
36 Decreased viability GR00221-A-3 10.35 BRCA1
37 Decreased viability GR00221-A-4 10.35 BRAF
38 Decreased viability GR00301-A 10.35 BRCA1 BRAF CDH1 KRAS
39 Decreased viability GR00381-A-1 10.35 BRAF KRAS
40 Decreased viability GR00402-S-2 10.35 BRCA1 BRAF CDH1 KRAS
41 Decreased cell migration GR00055-A-1 9.8 BRAF CTNNB1 AKT1 PIK3CA KRAS
42 Increased cell migration GR00055-A-3 9.56 BRAF KRAS CTNNB1 PIK3CA
43 Decreased viability with cisplatin GR00101-A-4 9.5 BRCA1 BRCA2 BRIP1
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 BRCA1 AKT1 BRCA2 PALB2 PRKN PTEN
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 BRCA1 AKT1 BRCA2 BRAF BRIP1 PALB2
46 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 BRIP1

MGI Mouse Phenotypes related to Ovarian Cancer:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 BRAF BRIP1 BRCA1 AKT1 BRCA2 PIK3CA
2 cardiovascular system MP:0005385 10.26 BRAF BRCA1 AKT1 KRAS PRKN CDH1
3 growth/size/body region MP:0005378 10.23 BRCA2 BRAF BRCA1 AKT1 PIK3CA PRKN
4 embryo MP:0005380 10.19 CDH1 BRCA1 AKT1 BRCA2 BRAF KRAS
5 endocrine/exocrine gland MP:0005379 10.18 BRAF BRIP1 BRCA1 AKT1 BRCA2 PIK3CA
6 integument MP:0010771 10.17 CDH1 BRCA1 AKT1 BRCA2 BRAF KRAS
7 neoplasm MP:0002006 10.15 BRIP1 CDH1 BRCA1 AKT1 BRCA2 BRAF
8 nervous system MP:0003631 10.06 BRCA2 BRAF BRIP1 BRCA1 AKT1 CTNNB1
9 muscle MP:0005369 10.01 BRAF BRCA1 AKT1 PIK3CA PRKN KRAS
10 normal MP:0002873 9.91 BRCA2 BRAF BRCA1 AKT1 PRKN KRAS
11 reproductive system MP:0005389 9.65 BRAF BRIP1 BRCA1 AKT1 BRCA2 KRAS
12 pigmentation MP:0001186 9.55 BRAF BRCA1 CTNNB1 KRAS PTEN
13 skeleton MP:0005390 9.28 BRCA2 BRAF BRCA1 AKT1 CTNNB1 PIK3CA

Drugs & Therapeutics for Ovarian Cancer

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
CEA-Scan 18 Immunomedics April 1996
2
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
3
Ethyol 18 AMIFOSTINE Alza December 8, 1995
4
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
5
Iressa 18 49 GEFITINIB AstraZeneca May 2003
6
Lynparza 18 49 OLAPARIB AstraZeneca December 2014

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
3
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 763113-22-0 23725625
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 151165 6918365
9
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
10
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
11
Peppermint Approved, Nutraceutical Phase 4
12
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
13
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 11103-57-4, 68-26-8 445354
14
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
15
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
16 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Ferrous fumarate Phase 4,Not Applicable,Early Phase 1
41 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antifibrinolytic Agents Phase 4
45 Coagulants Phase 4,Phase 2,Not Applicable
46 Hemostatics Phase 4,Phase 2,Not Applicable
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 neurokinin A Phase 4,Phase 2,Not Applicable
50 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2381)
# Name Status NCT ID Phase Drugs
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
2 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
3 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
6 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
7 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
8 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
9 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
10 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
11 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
12 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
13 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
14 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
15 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
16 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
17 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
18 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
19 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
20 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
21 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
22 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
23 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
24 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
25 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
26 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
27 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
28 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
29 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
30 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
31 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
32 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
33 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
34 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
35 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
36 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
37 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
38 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
39 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
40 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
41 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
42 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
43 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
44 Women's Activity and Lifestyle Study in Connecticut Completed NCT02107066 Phase 3
45 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed NCT00113607 Phase 3 Trabectedin;DOXIL;Dexamethasone
46 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
47 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
48 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
49 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3 Topotecan
50 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer Completed NCT00102414 Phase 3 Gemcitabine

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 29 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 29

Anatomical Context for Ovarian Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

19
The Ovary

MalaCards organs/tissues related to Ovarian Cancer:

41
Ovary, Testes, Lung, T Cells, Breast, Endothelial, Bone

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 8728)
# Title Authors Year
1
A prognostic 11 genes expression model for ovarian cancer. ( 28817186 )
2018
2
Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells. ( 29301278 )
2018
3
Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers. ( 29952249 )
2018
4
Triptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751. ( 29966441 )
2018
5
miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. ( 29436681 )
2018
6
The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin. ( 28771721 )
2018
7
Precise preoperative diagnosis of struma ovarii with pseudo-Meigs' syndrome mimicking ovarian cancer with the combination of<sup>131</sup>I scintigraphy and<sup>18</sup>F-FDG PET: case report and review of the literature. ( 29391043 )
2018
8
Characteristics of Lynch syndrome associated ovarian cancer. ( 29880284 )
2018
9
Are patients willing to travel for better ovarian cancer care? ( 29079037 )
2018
10
A Miniature Cell Pattern Formation of Ovarian Cancer Cell Lines on Self-Assembling Peptide Nanofiber-Coated Coverslip and<i>In Vitro</i>Chemosensitivity Assay. ( 29442905 )
2018
11
The Yet Unrealized Promise of Ovarian Cancer Screening. ( 29450480 )
2018
12
Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells. ( 29436692 )
2018
13
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. ( 29450531 )
2018
14
Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report. ( 29979376 )
2018
15
miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1. ( 29445078 )
2018
16
Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. ( 29973223 )
2018
17
MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. ( 28057486 )
2018
18
Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. ( 29979793 )
2018
19
Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer. ( 28891089 )
2018
20
Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. ( 29480828 )
2018
21
Orlistat induces apoptosis and protective autophagy in ovarian cancer cells: involvement of Akt-mTOR-mediated signaling pathway. ( 29974191 )
2018
22
GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. ( 29973689 )
2018
23
Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer? ( 29967225 )
2018
24
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study. ( 29451070 )
2018
25
Evaluation of Factors Affecting Lymph Node Metastasis in Clinical Stage I-II Epithelial Ovarian Cancer. ( 29975960 )
2018
26
Palmar fasciitis with polyarthritis-associated ovarian cancer: Case report and literature review. ( 29435290 )
2018
27
Phagocytosis of Extracellular Vesicles Extruded From the Placenta by Ovarian Cancer Cells Inhibits Growth of the Cancer Cells. ( 29040188 )
2018
28
Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells. ( 29251331 )
2018
29
Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. ( 29134372 )
2018
30
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients. ( 29782365 )
2018
31
MiR-628-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at FGFR2. ( 29229394 )
2018
32
Paclitaxel and Pazopanib in Ovarian Cancer-Reply. ( 29978183 )
2018
33
Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack? ( 29980529 )
2018
34
Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion. ( 29970688 )
2018
35
Screening for Ovarian Cancer in Asymptomatic Women. ( 29450509 )
2018
36
Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response. ( 28481779 )
2018
37
Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70<sup>S6K</sup>with Dendrimer Nanovector-Based siRNA Delivery. ( 29241971 )
2018
38
Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. ( 29303933 )
2018
39
Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer. ( 29975922 )
2018
40
Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity. ( 29437202 )
2018
41
Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium. ( 29247577 )
2018
42
14-3-3IP Overexpression is Associated with Poor Prognosis in Ovarian Cancer. ( 29214776 )
2018
43
Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer. ( 29976638 )
2018
44
Association between average daily television viewing time and the incidence of ovarian cancer: findings from the Japan Collaborative Cohort Study. ( 29340890 )
2018
45
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer. ( 29324448 )
2018
46
A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. ( 29248198 )
2018
47
Serum B7 homologous body 4 for the diagnosis of ovarian cancer in Chinese Han women: A meta-analysis. ( 29970702 )
2018
48
BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer. ( 29194191 )
2018
49
Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( 29450530 )
2018
50
Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer. ( 29385863 )
2018

Variations for Ovarian Cancer

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer:

75
# Symbol AA change Variation ID SNP ID
1 BRCA1 p.Cys61Gly VAR_007757 rs28897672
2 BRCA1 p.Cys1697Arg VAR_020702 rs80356993
3 BRCA1 p.Arg1699Trp VAR_075666 rs55770810
4 CTNNB1 p.Ser37Cys VAR_017625 rs121913403
5 CTNNB1 p.Thr41Ile VAR_017630 rs121913413
6 OPCML p.Pro95Arg VAR_055421 rs137852691
7 PIK3CA p.His1047Arg VAR_026192 rs121913279

ClinVar genetic disease variations for Ovarian Cancer:

6
(show top 50) (show all 251)
# Gene Variation Type Significance SNP ID Assembly Location
1 PRKN PARK2, DEL deletion Pathogenic
2 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
3 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic rs121909224 GRCh38 Chromosome 10, 87933147: 87933147
4 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
5 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
6 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh37 Chromosome 11, 132527098: 132527098
7 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh38 Chromosome 11, 132657203: 132657203
8 RRAS2 NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu) single nucleotide variant Pathogenic rs113954997 GRCh37 Chromosome 11, 14316390: 14316390
9 RRAS2 NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu) single nucleotide variant Pathogenic rs113954997 GRCh38 Chromosome 11, 14294844: 14294844
10 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
11 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
12 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
13 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
14 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
15 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
16 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
17 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
18 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
19 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
20 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
21 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
22 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
23 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
24 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
25 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
26 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
27 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
28 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
29 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
30 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
31 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
32 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
33 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh37 Chromosome 17, 37881378: 37881378
34 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh38 Chromosome 17, 39725125: 39725125
35 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
36 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
37 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
38 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
39 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
40 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
41 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
42 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
43 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh38 Chromosome 3, 41224622: 41224622
44 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
45 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh38 Chromosome 3, 41224613: 41224613
46 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
47 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh38 Chromosome 3, 41224622: 41224622
48 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
49 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh38 Chromosome 17, 43057065: 43057065
50 ABCG2 NM_004827.2(ABCG2): c.421C> A (p.Gln141Lys) single nucleotide variant drug response rs2231142 GRCh37 Chromosome 4, 89052323: 89052323

Cosmic variations for Ovarian Cancer:

9
(show all 44)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 19
2 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 19
3 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 19
4 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 19
5 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 19
6 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 19
7 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 19
8 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 19
9 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 19
10 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 19
11 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 3:179218294-179218294 19
12 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 19
13 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 19
14 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 19
15 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 19
16 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 19
17 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 19
18 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 19
19 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 12:25245350-25245350 19
20 COSM521 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 19
21 COSM520 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 12:25245350-25245350 19
22 COSM14065 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 19
23 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 19
24 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 19
25 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 19
26 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 19
27 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 7:55173971-55173971 19
28 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 19
29 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 19
30 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 19
31 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 19
32 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 7:55174769-55174769 19
33 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 7:55191808-55191808 19
34 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 19
35 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 19
36 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 7:55191730-55191730 19
37 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 19
38 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 19
39 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 19
40 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 19
41 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 19
42 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 19
43 COSM6904304 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 19
44 COSM159008 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 19

Copy number variations for Ovarian Cancer from CNVD:

7 (show top 50) (show all 8010)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13413 1 1 23549970 Deletion AADACL3 Ovarian cancer
2 13414 1 1 23549970 Deletion AADACL4 Ovarian cancer
3 13415 1 1 23549970 Deletion ACAP3 Ovarian cancer
4 13416 1 1 23549970 Deletion ACOT7 Ovarian cancer
5 13417 1 1 23549970 Deletion ACTL8 Ovarian cancer
6 13418 1 1 23549970 Deletion ACTRT2 Ovarian cancer
7 13419 1 1 23549970 Deletion AGMAT Ovarian cancer
8 13420 1 1 23549970 Deletion AGRN Ovarian cancer
9 13421 1 1 23549970 Deletion AGTRAP Ovarian cancer
10 13422 1 1 23549970 Deletion AJAP1 Ovarian cancer
11 13423 1 1 23549970 Deletion AKR7A2 Ovarian cancer
12 13424 1 1 23549970 Deletion AKR7A3 Ovarian cancer
13 13425 1 1 23549970 Deletion AKR7L Ovarian cancer
14 13426 1 1 23549970 Deletion ALDH4A1 Ovarian cancer
15 13427 1 1 23549970 Deletion ALPL Ovarian cancer
16 13428 1 1 23549970 Deletion ANGPTL7 Ovarian cancer
17 13429 1 1 23549970 Deletion APITD1 Ovarian cancer
18 13430 1 1 23549970 Deletion ARHGEF10L Ovarian cancer
19 13431 1 1 23549970 Deletion ARHGEF16 Ovarian cancer
20 13432 1 1 23549970 Deletion ARHGEF19 Ovarian cancer
21 13433 1 1 23549970 Deletion ATAD3A Ovarian cancer
22 13434 1 1 23549970 Deletion ATAD3B Ovarian cancer
23 13435 1 1 23549970 Deletion ATAD3C Ovarian cancer
24 13436 1 1 23549970 Deletion ATP13A2 Ovarian cancer
25 13437 1 1 23549970 Deletion AURKAIP1 Ovarian cancer
26 13438 1 1 23549970 Deletion B3GALT6 Ovarian cancer
27 13439 1 1 23549970 Deletion C1QA Ovarian cancer
28 13440 1 1 23549970 Deletion C1QB Ovarian cancer
29 13441 1 1 23549970 Deletion C1QC Ovarian cancer
30 13442 1 1 23549970 Deletion C1orf126 Ovarian cancer
31 13443 1 1 23549970 Deletion C1orf127 Ovarian cancer
32 13444 1 1 23549970 Deletion C1orf144 Ovarian cancer
33 13445 1 1 23549970 Deletion C1orf151 Ovarian cancer
34 13446 1 1 23549970 Deletion C1orf158 Ovarian cancer
35 13447 1 1 23549970 Deletion C1orf159 Ovarian cancer
36 13448 1 1 23549970 Deletion C1orf170 Ovarian cancer
37 13449 1 1 23549970 Deletion C1orf174 Ovarian cancer
38 13450 1 1 23549970 Deletion C1orf187 Ovarian cancer
39 13451 1 1 23549970 Deletion C1orf200 Ovarian cancer
40 13452 1 1 23549970 Deletion C1orf64 Ovarian cancer
41 13453 1 1 23549970 Deletion C1orf70 Ovarian cancer
42 13454 1 1 23549970 Deletion C1orf86 Ovarian cancer
43 13455 1 1 23549970 Deletion C1orf89 Ovarian cancer
44 13456 1 1 23549970 Deletion C1orf93 Ovarian cancer
45 13457 1 1 23549970 Deletion CA6 Ovarian cancer
46 13458 1 1 23549970 Deletion CALML6 Ovarian cancer
47 13459 1 1 23549970 Deletion CAMK2N1 Ovarian cancer
48 13460 1 1 23549970 Deletion CAMTA1 Ovarian cancer
49 13461 1 1 23549970 Deletion CAPZB Ovarian cancer
50 13462 1 1 23549970 Deletion CASP9 Ovarian cancer

Expression for Ovarian Cancer

Search GEO for disease gene expression data for Ovarian Cancer.

Pathways for Ovarian Cancer

Pathways related to Ovarian Cancer according to KEGG:

37
# Name Kegg Source Accession
1 MicroRNAs in cancer hsa05206

Pathways related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 AKT1 BRAF CDH1 CTNNB1 KRAS RRAS2
2
Show member pathways
13.03 AKT1 BRCA1 CTNNB1 KRAS PIK3CA PTEN
3
Show member pathways
12.98 AKT1 BRCA1 BRCA2 BRIP1 KRAS RRAS2
4
Show member pathways
12.95 AKT1 BRAF CDH1 CTNNB1 KRAS PTEN
5
Show member pathways
12.91 AKT1 BRAF KRAS PIK3CA PTEN RRAS2
6
Show member pathways
12.85 AKT1 BRAF CTNNB1 KRAS RRAS2
7
Show member pathways
12.84 AKT1 BRAF KRAS PTEN RRAS2
8
Show member pathways
12.84 AKT1 BRAF KRAS PTEN RRAS2
9
Show member pathways
12.83 AKT1 BRAF CTNNB1 KRAS MIR34C PIK3CA
10
Show member pathways
12.78 AKT1 BRAF BRCA2 CDH1 CTNNB1 KRAS
11
Show member pathways
12.74 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
12
Show member pathways
12.72 AKT1 CTNNB1 KRAS PIK3CA PTEN
13
Show member pathways
12.7 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
14 12.69 AKT1 BRAF BRCA2 CDH1 CTNNB1 KRAS
15
Show member pathways
12.62 AKT1 CTNNB1 KRAS PIK3CA PTEN
16
Show member pathways
12.59 AKT1 BRAF BRCA1 BRCA2 CDH1 KRAS
17
Show member pathways
12.55 AKT1 BRAF KRAS PIK3CA PTEN
18
Show member pathways
12.48 AKT1 CTNNB1 KRAS PIK3CA
19
Show member pathways
12.48 AKT1 BRAF KRAS RRAS2
20
Show member pathways
12.48 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
21 12.47 AKT1 CTNNB1 KRAS PIK3CA RRAS2
22
Show member pathways
12.44 AKT1 KRAS PIK3CA RRAS2
23
Show member pathways
12.43 AKT1 BRAF KRAS PIK3CA PTEN
24
Show member pathways
12.43 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
25
Show member pathways
12.4 AKT1 BRAF KRAS PIK3CA
26
Show member pathways
12.4 AKT1 BRAF BRCA1 CTNNB1 KRAS PIK3CA
27
Show member pathways
12.37 AKT1 KRAS PIK3CA PTEN
28
Show member pathways
12.34 AKT1 BRAF PIK3CA RRAS2
29
Show member pathways
12.34 BRCA1 BRCA2 BRIP1 PALB2
30
Show member pathways
12.31 BRAF CDH1 CTNNB1 PIK3CA
31
Show member pathways
12.26 AKT1 KRAS PIK3CA RRAS2
32 12.26 AKT1 BRAF CTNNB1 KRAS PIK3CA RRAS2
33 12.24 AKT1 BRAF KRAS PTEN
34
Show member pathways
12.23 AKT1 BRAF KRAS PIK3CA
35 12.22 AKT1 BRAF CDH1 CTNNB1 KRAS
36 12.2 AKT1 KRAS PIK3CA PTEN
37 12.2 AKT1 KRAS PIK3CA PTEN RRAS2
38
Show member pathways
12.19 AKT1 BRAF KRAS RRAS2
39
Show member pathways
12.19 BRCA1 BRCA2 BRIP1 PALB2
40
Show member pathways
12.19 AKT1 KRAS PIK3CA PTEN
41
Show member pathways
12.17 AKT1 CTNNB1 PIK3CA PTEN
42 12.14 AKT1 CTNNB1 KRAS PIK3CA
43 12.13 AKT1 CDH1 KRAS RRAS2
44
Show member pathways
12.13 AKT1 BRAF KRAS PIK3CA PTEN
45
Show member pathways
12.12 AKT1 BRCA1 CDH1 KRAS PIK3CA RRAS2
46 12.11 AKT1 BRAF KRAS PIK3CA
47 12.09 AKT1 KRAS PIK3CA PTEN RRAS2
48
Show member pathways
12.08 AKT1 BRAF CTNNB1 PIK3CA
49 12.08 BRCA1 KRAS MIR146A MIR200A MIR200B MIR200C
50
Show member pathways
12.07 AKT1 KRAS PIK3CA RRAS2

GO Terms for Ovarian Cancer

Cellular components related to Ovarian Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.99 AKT1 BRCA1 BRCA2 BRIP1 PALB2
2 regulation of cell proliferation GO:0042127 9.93 BRAF BRCA1 BRCA2 CTNNB1
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 AKT1 BRAF PIK3CA
4 double-strand break repair via homologous recombination GO:0000724 9.79 BRCA1 BRCA2 PALB2
5 negative regulation of gene expression GO:0010629 9.77 AKT1 BRIP1 CTNNB1 MIR200B PRKN
6 regulation of protein stability GO:0031647 9.76 KRAS PRKN PTEN
7 double-strand break repair GO:0006302 9.73 BRCA1 BRCA2 BRIP1
8 epidermal growth factor receptor signaling pathway GO:0007173 9.72 AKT1 KRAS PIK3CA
9 gene silencing by miRNA GO:0035195 9.72 MIR146A MIR200A MIR200B MIR200C MIR34C
10 negative regulation of neuron apoptotic process GO:0043524 9.71 BRAF KRAS PIK3CA PRKN
11 negative regulation of protein kinase B signaling GO:0051898 9.7 AKT1 MIR34C PTEN
12 negative regulation of neuron death GO:1901215 9.69 AKT1 CTNNB1 PRKN
13 protein kinase B signaling GO:0043491 9.67 AKT1 PIK3CA PTEN
14 cellular process GO:0009987 9.65 CTNNB1 RRAS2
15 negative regulation of macroautophagy GO:0016242 9.65 AKT1 PIK3CA
16 regulation of synaptic transmission, GABAergic GO:0032228 9.64 KRAS PTEN
17 inner cell mass cell proliferation GO:0001833 9.63 BRCA2 PALB2
18 entry of bacterium into host cell GO:0035635 9.62 CDH1 CTNNB1
19 anoikis GO:0043276 9.61 AKT1 PIK3CA
20 cellular response to nerve growth factor stimulus GO:1990090 9.61 AKT1 BRAF PTEN
21 negative regulation of cell size GO:0045792 9.6 AKT1 PTEN
22 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.58 CTNNB1 MIR146A
23 protein K6-linked ubiquitination GO:0085020 9.57 BRCA1 PRKN
24 DNA synthesis involved in DNA repair GO:0000731 9.56 BRCA1 BRCA2 BRIP1 PALB2
25 regulation of axon regeneration GO:0048679 9.54 BRAF PTEN
26 chordate embryonic development GO:0043009 9.48 BRCA1 BRCA2
27 cellular response to decreased oxygen levels GO:0036294 9.46 AKT1 PTEN
28 cellular response to indole-3-methanol GO:0071681 9.33 BRCA1 CDH1 CTNNB1
29 strand displacement GO:0000732 9.26 BRCA1 BRCA2 BRIP1 PALB2
30 positive regulation of gene expression GO:0010628 9.23 AKT1 BRAF BRCA1 CTNNB1 KRAS MIR146A
31 positive regulation of cell proliferation GO:0008284 10.04 AKT1 CTNNB1 KRAS MIR200B PTEN

Molecular functions related to Ovarian Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.26 MIR146A MIR200A MIR200B MIR200C
2 GTPase activating protein binding GO:0032794 9.16 AKT1 CDH1
3 enzyme binding GO:0019899 9.02 AKT1 BRCA1 CTNNB1 PRKN PTEN

Sources for Ovarian Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....